# A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

> **NCT07059299** · PHASE1 · RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 18 (estimated)

## Conditions studied

- Esophagogastric Junction Adenocarcinoma
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma
- Resectable Esophagogastric Adenocarcinoma
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** FLOT Chemotherapy

## Key facts

- **NCT ID:** NCT07059299
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059299, "A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07059299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*